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Oxidative stressGuanosine is a guanine-based purine that modulates glutamate uptake and exerts neurotrophic and neuropro-
tective effects. In a previous study, our group demonstrated that this endogenous nucleoside displays
antidepressant-like properties in a predictive animal model. Based on the role of oxidative stress in modulating
depressive disorders as well as on the association between the neuroprotective and antioxidant properties of
guanosine, here we investigated if its antidepressant-like effect is accompanied by a modulation of hippocampal
oxidant/antioxidant parameters. Adult Swiss mice were submitted to an acute restraint stress protocol, which is
known to cause behavioral changes that are associated with neuronal oxidative damage. Animals submitted to
ARS exhibited an increased immobility time in the forced swimming test (FST) and the administration of guano-
sine (5 mg/kg, p.o.) or ﬂuoxetine (10 mg/kg, p.o., positive control) before the exposure to stressor prevented this
alteration. Moreover, the signiﬁcantly increased levels of hippocampal malondialdehyde (MDA; an indicator of
lipid peroxidation), induced by ARS were not observed in stressed mice treated with guanosine. Although no
changes were found in the hippocampal levels of reduced glutathione (GSH), the group submitted to ARS proce-
dure presented enhanced glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase
(SOD) activities and reduced catalase (CAT) activity in the hippocampus. Guanosine was able to prevent the al-
terations inGPx, GR, CAT activities, and in SOD/CAT activity ratio, but potentiated the increase in SOD activity elic-
ited by ARS. Altogether, the present ﬁndings indicate that the observed antidepressant-like effects of guanosine
might be related, at least in part, to its capability of modulating antioxidant defenses andmitigating hippocampal
oxidative damage induced by ARS.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Stressful life experiences are recognized as amajor risk factor for car-
diovascular, metabolic and neuropsychiatric diseases (Musazzi et al.,
2010). Among the stress related psychiatry disorders, a great amount
of evidence indicates the involvement of stressful eventswithmajor de-
pression, a debilitating disease with high prevalence worldwide
(Krishnan and Nestler, 2008; Paykel, 2003). This observation can be ex-
plained by the occurrence of morphological remodeling as well ase restraint stress; CAT, catalase;
SSG, glutathione disulﬁde; GPx,
ducedglutathione;H2O2,hydro-
ase-1;MDA,malondialdehyde;
hate; NPSH, non-protein thiols;
eroxideanion radical;ROS, reac-
S, thiobarbituric acid reactive
55 48 3721 9672.
ail.com (A.L.S. Rodrigues).molecular, neurochemical and electrophysiological changes associated
with stress that can lead to the cognitive deﬁcits observed in depressive
patients (Herman and Cullinan, 1997). In this scenario, the hippocam-
pus, an encephalic area that plays a key role in learning and memory,
is also deeply involved in the pathophysiology of depression and in
the action of antidepressant drugs (Kim et al., 2012; McEwen, 1999,
2000). Due to its high levels of glucocorticoid receptors (themain intra-
cellularmediators of stress response), this brain structure is particularly
sensitive to stressful events (McEwen, 2005). Moreover, the hippocam-
pus is interconnected and exerts synaptic inﬂuence in the prefrontal
cortex and amygdala, which are also key structures implicated in de-
pression (Degenetais et al., 2003; Ishikawa and Nakamura, 2003; Price
and Drevets, 2010). This integrated circuitry suggests that the hippo-
campus is functionally related with these structures. Therefore, an im-
pairment in its function caused by stress may cause neurochemical
dysfunctions in neuroplasticity pathways in distinct corticolimbic re-
gions (Godsil et al., 2013).
The acute exposition to a stressful event and the consequent increase
in circulating levels of glucocorticoids induce a rapid depolarization-
evoked glutamate release in cortical and limbic regions (Lowy et al.,
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role in neuronal plasticity through the activation of its synaptic receptors
(Mattson, 2008). However, excessive levels of glutamate can cause an
overstimulation of extrasynaptic receptors, leading to mitochondrial
dysfunction, impairment in the cellular calcium homeostasis and
generation of reactive oxygen species (ROS) (Hardingham et al.,
2002; Reynolds and Hastings, 1995).
The precursor of most ROS is superoxide anion (O2•−) a product
of the reduction of oxygen by one electron. Its dismutation produces hy-
drogen peroxide (H2O2), which in turnmay be fully reduced to water or
partially reduced to hydroxyl radical (OH•), one of the strongest oxi-
dants in nature (Turrens, 2003). AlthoughROS participate in normal cel-
lular processes, they may cause damage to cell components including
proteins, nucleic acids, carbohydrates and lipids when associated with
an imbalance in antioxidant capacity (Hovatta et al., 2010). Human de-
fenses against excessive ROS generation include the enzyme superoxide
dismutase (SOD), which accelerates the dismutation of O2•− into H2O2
and molecular oxygen. Thereafter, H2O2 is decomposed by glutathione
peroxidase (GPx) or by catalase (CAT) (Turrens, 2003). Besides, many
different agents are involved in the nonenzymatic detoxiﬁcation of
ROS including glutathione (GSH), the main nonprotein thiol of the
mammalian cell. This tripeptide protects cells by serving as a substrate
in the cytosolic redox cycle or directly inactivating ROS such as O2•− or
OH• (Knapen et al., 1999).
Due to its high rate of oxygen consumption, the central nervous sys-
tem (CNS) is especially vulnerable to excessive generation of free radi-
cals (Lee et al., 2012) and oxidative damage to neurons has been
implicated in the pathogenesis of depression (Zhang and Yao, 2013).
Therefore, the involvement of ROS-mediated pathways and lowered
levels of antioxidants in the pathogenesis of depression have been
target of several investigations, some of which have pointed to neuroin-
ﬂammation and altered neurogenesis/neuroplasticity as pivotal phe-
nomena (Maes et al., 2011a). Depressive patients have signiﬁcantly
elevated plasma levels of peroxide in comparison with normal controls
(Maes et al., 2010) as well as higher levels of malondialdehyde (MDA),
an indicative of the occurrence of oxidative stress (Ozcan et al., 2004;
Sarandol et al., 2007). As mentioned above, this excessive ROS produc-
tion can be neutralized by different antioxidant enzymes like superox-
ide dismutase (SOD), glutathione peroxidase (GPx) or catalase (CAT),
which have been reported to be altered in depressive patients
(Galecki et al., 2009; Maes et al., 2011b; Ozcan et al., 2004; Sarandol
et al., 2007).
Supporting this hypothesis, there is increasing evidence demon-
strating that current antidepressants used in clinical practice may
exert their therapeutic effect by regulating oxidative stress (Herken
et al., 2007; Khanzode et al., 2003; Kotan et al., 2011). Taking this into
account, it is not surprising that novel antidepressant targets are being
considered for investigation based on their antioxidant properties (Lee
et al., 2012), since conventional antidepressants present side effects
and may afford incomplete remission (Katalinic et al., 2013; Niciu
et al., 2014).
In this context, guanosine, a guanine-based nucleoside that ex-
hibits protective effects against glutamate excitotoxicity (Frizzo
et al., 2002; Vinade et al., 2005) and oxidative stress (Dal-Cim
et al., 2012; Petronilho et al., 2012; Tarozzi et al., 2010), represents
an interestingmolecule for investigation. In fact, we recently demon-
strated that the administration of this nucleoside produces an
antidepressant-like effect in the tail suspension test (TST) and in
the forced swimming test (FST) similar to the one produced by ﬂuox-
etine (Bettio et al., 2012); however, the involvement of this effect
with hippocampal anti-/pro-oxidative events has not yet been inves-
tigated. Considering this background, the present study investigated
the protective effect of guanosine against behavioral alterations in
the forced swimming test and hippocampal antioxidant imbalance
induced by the acute restraint stress (ARS) protocol (Kumar et al.,
2010; Moretti et al., 2013; Freitas et al., 2014).2. Materials and methods
2.1. Animals
Female Swiss mice (35–45 g), maintained at 20–22 °C with free ac-
cess towater and food and under a 12:12 h light/dark cycle (lights on at
7:00 a.m.) were used. The animals were caged in groups of 15 in a
41 × 34 × 16 cm cage. All behavioral tests were carried out between
9:00 a.m. and 5:00 p.m. Mice were used according to the NIH Guide
for the Care and Use of Laboratory Animals and the experiments were
performed after approval of the protocol by the Ethics Committee of
the Institution. All efforts were made to minimize animal suffering
and to reduce the number of animals used in the experiments.
2.2. Drugs and treatment
Guanosine and ﬂuoxetine (obtained from Sigma Chemical Co., St.
Louis, USA) were dissolved in distilled water and administered orally
(p.o.) at a dose of 5 and 10 mg/kg, respectively, 1 h before the ARS pro-
cedure. The doses used were chosen based on previous studies (Bettio
et al., 2012;Moretti et al., 2013). Solutionswere freshly prepared before
administration and administered in a volume of 10 ml/kg. The
nonstressed group (control) received distilled water by p.o. route
(10 ml/kg). To develop this study, mice were divided into four groups
as follows: (1) nonstressed + vehicle; (2) nonstressed + guanosine;
(3) stressed + vehicle; and (4) stressed + guanosine. The number of
mice per group was 7–9. Fluoxetine was added as a positive control in
the forced swimming test (FST) and open ﬁeld test in another set of
experiments.
2.3. Acute restraint stress procedure
ARS protocol was performed as previously described (Freitas et al.,
2014; Moretti et al., 2013) 1 h after the treatment with vehicle, guano-
sine or ﬂuoxetine. The immobilization was applied for a period of 7 h
using an individual rodent restraint devicemade of Plexiglas fenestrate,
restraining all physical movement without causing pain. The animals
were deprived of food and water during the entire period of exposure
to stress. Non-stressed groups (controls) were treated with vehicle or
guanosine and were kept without food and water for 7 h (the same
time period of stress). After this time period, independent groups of
mice were released from their enclosure and 40 min post-release
were submitted to the FST, to the open ﬁeld test and were sacriﬁced
for the biochemical studies. The control group was submitted to the
same protocol, except that it was not submitted to stress.
2.4. Behavioral tests
2.4.1. Forced swimming test
Brieﬂy, mice were individually forced to swim in an open cylindrical
container (diameter 10 cm, height 25 cm), containing 19 cm of water
(depth) at 25±1 °C; the total duration of immobilitywasmeasured dur-
ing a 6-min test period by observers blind to the treatment conditions.
Each mouse was judged to be immobile when it ceased struggling and
remained ﬂoating motionless in the water, making only those move-
ments necessary to keep its head above water (Porsolt et al., 1977).
2.4.2. Open ﬁeld test
To assess possible interferences on locomotor activity, mice were
evaluated in the open ﬁeld paradigm as previously described. Animals
were individually placed in a wooden box (40 × 60 × 50 cm) with the
ﬂoor divided into 12 equal squares and the number of crossings with
all paws was manually counted in a 6-min session. The light was main-
tained at minimum to avoid anxiety behavior and the apparatus was
cleaned with a solution of 10% ethanol between tests in order to hide
animal clues (Budni et al., 2013; Moretti et al., 2013).
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2.5.1. Tissue preparation
1 h after the ARS procedure, animals were killed by decapitation and
the hippocampi were removed and homogenized (1:10 w/v) in HEPES
buffer (20 mM, pH 7.0). The tissue homogenates were centrifuged at
16,000 × g, at 4 °C for 20 min and the supernatants obtained were
used for the determination of enzymatic activities and for the quantiﬁ-
cation of GSH levels and thiobarbituric acid reactive substances
(TBARS). The protein content was quantiﬁed by the method of Lowry
et al. (1951) using bovine serum albumin as standard. Tissue samples
were frozen in liquid nitrogen and stored at−80 °C in order to deter-
mine the activity of antioxidant enzymes later.
2.5.2. Activity of antioxidant enzymes
Hippocampal glutathione reductase (GR) activity was determined
based on the protocol developed by Carlberg and Mannervik (1985).
Brieﬂy, GR reduces glutathione disulﬁde (GSSG) to GSH at the expense
of NADPH. Thus, GR activity was monitored by decreases in NADPH ab-
sorbance at 340 nm at 37 °C. Results were based on a molar extinction
coefﬁcient for NADPH of 6.22 × 103 M−1 cm−1.
GPx uses GSH to reduce the tert-butyl hydroperoxide, producing
GSSG,which is readily reduced to GSH by GR usingNADPH as a reducing
equivalent donor. Hippocampal GPx activity was measured through a
NADPH reduction assay following the protocol developed by Wendel
(1981). Tissue supernatant (around 200 μg protein) was added to a re-
action mixture containing GSH, GR and NADPH in phosphate buffer
(pH 7.4). The reactionwas initiated by adding tert-butyl hydroperoxide,
and the absorbance decrease at 340 nmwas recorded at 37 °C. The activ-
ity in the absence of the samples was subtracted. Results were based on
a molar extinction coefﬁcient for NADPH of 6.22 × 103 M−1 cm−1. Both
GR and GPx activities were expressed as nmol NADPH oxidized/min/mg
protein.
CAT activity was measured by the method of Aebi (1984). The reac-
tion was started by the addition of freshly prepared 30 mM H2O2 and
the rate of its decomposition by CAT measured spectrophotometrically
at 240 nm (enzyme activity expressed as μmol H2O2 consumed/min/
mg protein).
SOD activity was assayed spectrophotometrically as described by
Misra and Fridovich (1972). This method is based on the capacity of
SOD to inhibit autoxidation of adrenaline to adrenochrome. The color
reaction was measured at 480 nm. One unit of enzyme was deﬁned as
the amount of enzyme required to inhibit the rate of epinephrine autox-
idation by50%. The SOD enzymatic activitywas expressed as units U/mg
protein. The spectrophotometer used for the assayswas a TECANGenios
Microplate Reader (Tecan Group Ltd., Männedorf, Switzerland).
2.5.3. Non-protein thiol groups determination
Glutathione (GSH) levels were measured as non-protein thiols
(NPSH), based on the protocol developed by Ellman (1959). This meth-
odology quantiﬁes only the reduced form of glutathione, which is re-
sponsible for the antioxidant properties of this peptide. In addition, a
small percentage (around 5%) of other low-molecular weight thiols is
also measured. Brieﬂy, hippocampal homogenates (fresh tissue) were
precipitated in 10% cooled trichloroacetic acid and centrifuged at
5000 ×g for 10 min, and the supernatant was incubated with DTNB
(5, 5′-dithio-bis(2-nitrobenzoic acid)) in a 1 M phosphate buffer,
pH 7.0. Absorbances were measured at 412 nm. A standard curve of
reduced glutathione was used to calculate GSH levels, which were
expressed as nmol of NPSH/mg protein.
2.5.4. Thiobarbituric acid reactive species (TBARS) formation
Thiobarbituric acid reactive species (TBARS) formation, a measure-
ment of lipid peroxidation, was determined in the homogenates from
fresh tissue according to the method described by Ohkawa et al.
(1979) in which MDA, an end-product of lipid peroxidation, reactswith thiobarbituric acid (TBA) to form a colored complex. The samples
were incubated at 100 °C for 60 min in acid medium containing 0.45%
sodium dodecyl sulfate and 0.67% thiobarbituric acid. After centrifuga-
tion, the reaction product was determined at 532 nm using MDA as
standard.
2.6. Statistical analysis
All data are presented as mean ± SEM. Differences among experi-
mental groups were determined by two-way ANOVA followed by
Duncan'smultiple range post hoc test.Main effects ofﬁrst order interac-
tion are presented only when interaction was not signiﬁcant. A value of
p b 0.05 was considered to be signiﬁcant.
3. Results
3.1. Guanosine and ﬂuoxetine prevented the increased immobility time
induced by ARS in the FST
The FST is the most widely used behavioral test to measure the
antidepressant-like activity of drugs and compounds. Based on its high
predictive validity, it was used to evaluate the inﬂuence of the treat-
ment with guanosine (5 mg/kg, p.o.) on the immobility time of mice
submitted toARS procedure. The two-wayANOVArevealed a signiﬁcant
main effect for guanosine treatment [F(1,29) = 14.11, p b 0.01], restraint
stress [F(1,29) = 10.76, p b 0.01] but not for ARS × guanosine treatment
interaction [F(1,29) = 0.018, p= 0.89]. Post hoc analysis indicated that
animals treated with guanosine alone exhibited a signiﬁcant reduction
in the immobility time (Fig. 1A, p b 0.05) compared to control group.
Although mice submitted to restraint stress showed an increase in the
immobility time (p b 0.05), animals submitted to restraint stress and
treated with guanosine presented immobility time similar to that ob-
served in control animals.
In another set of experiments, the selective serotonin reuptake in-
hibitor ﬂuoxetine (10 mg/kg, p.o.) was administered orally to evaluate
the inﬂuence of a positive control in the increased immobility time elic-
ited by ARS procedure in the FST (Fig. 1C). The treatment with this an-
tidepressant prevented the behavioral changes induced by stress
[F(1,27) = 4.51, p b 0.05]. In addition, nonstressedmice treated with ﬂu-
oxetine did not demonstrate alterations in immobility time as com-
pared to the control group.
3.2. ARS, guanosine and/or ﬂuoxetine did not alter locomotor activity
Fig. 1B illustrates the evaluation of locomotor activity obtained in the
open ﬁeld test to rule out the existence of nonspeciﬁc motor effects of
stress or treatment with guanosine in FST. Two-way ANOVA revealed
no signiﬁcant differences of guanosine treatment [F(1,30) = 0.38, p =
0.53], ARS [F(1,30) = 0.60, p = 0.44] and ARS × treatment interaction
[F(1,30) = 1.12, p= 0.29], indicating that the treatments did not affect
the spontaneous locomotor activity of mice. Moreover, Fig. 1D shows
that ﬂuoxetine was not able to induce signiﬁcant changes in the open
ﬁeld test as evidenced by two-way ANOVA of the treatment [F(1,26) =
0.48, p= 0.49], ARS [F(1,26) = 0.45, p= 0.51] and ARS × treatment in-
teraction [F(1,26) = 4.01, p= 0.06].
3.3. Guanosine protected mice hippocampus against lipid peroxidation in-
duced by ARS
Due to the short half-life of ROS it is difﬁcult tomeasure themdirect-
ly. Therefore, hippocampal TBARS levels weremeasured, sinceMDA is a
late product of lipid peroxidation. An increased production of MDA is
indicative of the occurrence of oxidative damage tomembranes, leading
to a compromised function and integrity of the cells. In our study, mice
submitted to ARS protocol presented a signiﬁcant increase in hippocam-
pal TBARS, whichwas abolished by guanosine treatment [F(1,31) = 4.75,
Fig. 1. Effect of treatmentwith guanosine (5 mg/kg) or ﬂuoxetine (10 mg/kg) on immobility time in the FST (A, C) and on locomotor activity in the openﬁeld test (B, D) inmice submitted
to ARS procedure. Each column represents themean± S.E.M. (n= 7–9). Statistical analysis was performed by two-way ANOVA, followed by the Duncan's test. *p b 0.05 vs. control mice,
#p b 0.05 vs. stress + vehicle group.
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stressedmice in comparison to nonstressedmice (p b 0.01) and a signif-
icant reduction in these levels in stressed mice treated with guanosine
(p b 0.05). Treatment of nonstressed group did not produce any signif-
icant effect on hippocampal TBARS levels.Fig. 2. Effect of treatment with guanosine (5 mg/kg) on thiobarbituric acid reactive sub-
stances (TBARS) (A) and on glutathione levels (B) in the hippocampus of mice submitted
to acute restraint stress procedure. Each column represents mean the ± SEM (n= 7–9).
**p b 0.01 vs. control mice, #p b 0.05 vs. stress + vehicle group.3.4. Antioxidant proﬁle of mice treated with guanosine and submitted to
ARS procedure
GSH is the main nonprotein thiol of the mammalian cell and is in-
volved in the antioxidant response by detoxiﬁcation of ROS, thus main-
taining the redox balance and preventing cell damage. As shown in
Fig. 2B, stressed animals did not show any alteration in GSH levels
[F(1,34) = 1.86, p = 0.18] and guanosine treatment did not inﬂuence
GSH levels in stressed [F(1,34) = 0.10, p = 0.92] or nonstressed mice
[F(1,34) = 0.07, p= 0.78].
The GSH-dependent detoxiﬁcation mechanisms involve the enzyme
GPx, which reduces peroxides to the corresponding stable alcohols and
water. This reaction produces GSSG, which can be converted back to
GSH in a reaction catalyzed by GR, at the expense of the reduction of
equivalents from NADPH. Regarding GPx activity, the two-way ANOVA
revealed a signiﬁcant main effect of ARS procedure [F(1,31) = 7.57,
p b 0.01] and guanosine treatment [F(1,31) = 0.79, p = 0.38] but not
guanosine × ARS interaction [F(1,31) = 1.48, p= 0.23]. Post hoc analysis
indicated that the exposure to ARS resulted in an enhanced hippocampal
activity of GPx (p b 0.05; Fig. 3A). In addition, the two-way ANOVA of GR
activity demonstrated a signiﬁcant effect of guanosine × ARS interaction
[F(1,31) = 5.90, p b 0.05] (Fig. 3B). Post hoc analysis found that ARS
induced an increased GR activity (p b 0.01) which was prevented by
guanosine treatment (p b 0.01).
Superoxide radicals (O2•−) are ROS generated as a by-product of mi-
tochondrial oxidative phosphorylation and from normal cellular bio-
chemical reactions but their excessive amounts can lead to cell
damage. The enzyme SOD catalyzes the dismutation of O2•− into H2O2
and is the ﬁrst line defense against these ROS. In our study, the two-
way ANOVA revealed a signiﬁcant effect to ARS× guanosine interaction
[F(1,29) = 4.52, p b 0.05]. The post hoc analysis indicated a signiﬁcantincrease in SOD activity in mice submitted to ARS procedure compared
with control group (p b 0.05, Fig. 4A). The treatmentwith guanosine did
not cause any alteration in the hippocampal activity of this enzyme in
nonstressed animals, however, it potentiated the stimulatory effect of
ARS toward this enzyme (p b 0.05).
Fig. 3. Effect of treatmentwith guanosine (5 mg/kg) on GPx activity (A) and on GR activity
(B) in thehippocampusofmice submitted to acute restraint stress. Each column represents
means ± SEM (n = 7–9). *p b 0.05, **p b 0.01 vs. control mice, ##p b 0.01 vs.
stress + vehicle group.
Fig. 4. Effect of treatment with guanosine (5 mg/kg) on SOD activity (A), CAT activity
(B) or SOD/CAT ratio (C) in the hippocampus of mice submitted to acute restraint stress
procedure. Each column representsmeans± SEM (n= 7–9). *p b 0.05, **p b 0.01 vs. con-
trol, #p b 0.05, ##p b 0.01 vs. stress + vehicle group.
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by SOD, is harmful formost cellular componentswhen accumulated. For
this reason, the rapid and efﬁcient removal of H2O2 is of essential impor-
tance for all aerobically living cells and CAT plays a signiﬁcant role for
this. The results illustrated in Fig. 4B demonstrate the effect of ARS
and guanosine in CAT activity. Two-way ANOVA revealed a signiﬁcant
difference for ARS × guanosine treatment [F(1,28) = 8.82, p b 0.01].
Post hoc analysis demonstrated thatmice submitted to ARS exhibits de-
creased hippocampal CAT activity in comparison to nonstressed mice
(p b 0.01). Guanosine treatment prevented this reduction in hippocam-
pal CAT activity caused by the exposition to ARS (p b 0.01), but did not
alter the activity of this enzyme in nonstressed animals.
Some lines of evidence indicate that increased SOD/CAT ratio favors
the maintenance of higher levels of H2O2, since SOD converts O2•− to
H2O2, but CAT is not able to metabolize H2O2 to water (Behr et al.,
2012; Halliwell, 2007). In order to evaluate a possible imbalance in
H2O2 production, the SOD/CAT ratio was calculated and showed in
Fig. 4C. Two-way ANOVA revealed a signiﬁcant alteration in SOD/CAT
ratio in stressed mice [F(1,28) = 8.70, p b 0.01] but not in stressed mice
treatedwith guanosine [F(1,28)= 1.72, p= 0.20] or nonstressed treated
mice [F(1,28) = 1.18, p = 0.28]. The post hoc analysis indicated an in-
crease in SOD/CAT ratio only in animals submitted to ARS treated with
vehicle (p b 0.01).4. Discussion
A recent study of our group demonstrated that the acute administra-
tion of guanosine exerts an antidepressant-like effect in two predictive
animal models, the TST and the FST (Bettio et al., 2012). However, the
ability of this nucleoside to counteract behavioral and biochemical alter-
ations induced by an acute stress was not evaluated in female mice,since depression is more prevalent and has a worse clinical outcome
inwomen (Patten et al., 2006). In this context, the present study sought
to investigate the protective effect of this nucleoside against oxidative
damage and the coping response to stress evaluated in the FST. The
ARS has been proposed as a model that triggers biochemical alterations
in mouse brain that can be harmful to CNS function. Among these
changes, an increased glutamate release (Satoh and Shimeki, 2010)
and an imbalance in oxidant/antioxidant parameters were reported in
rodents (Freitas et al., 2014; Kumar et al., 2010). This resulted increase
in ROS production and/or inefﬁciency in antioxidant systems leads to
oxidative stress and is implicated in several psychiatry diseases, includ-
ing major depression (Bilici et al., 2001; Valko et al., 2007).
The FST measures the immobility time of animals exposed to an in-
escapable situation and an increase in this parameter is considered a
passive behavior that disengages the animals from active forms of
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et al., 2013). In the present study, exposure to ARS caused an increased
immobility time in themouse FST as compared to the control group. In-
terestingly, the treatment with an oral dose of guanosine (5 mg/kg) re-
sulted in an antidepressant-like effect in nonstressed mice which was
not observed inmice administeredwithﬂuoxetine (10 mg/kg). This ab-
sence of effect observed in mice treated with ﬂuoxetine may be due to
the fact that this antidepressant was administered in a single dose 8 h
and 40min before the FST. The extended period of timewas not enough
to cause a reduction in the immobility time probably because the anti-
immobility effect ofﬂuoxetine is related to alterations that occur acutely
after its administration. The fact that only guanosine produced an
antidepressant-like effect in non-stressed mice reinforces the notion
that glutamatergic modulators display antidepressant properties that
differ from the monoaminergic agents (Zarate et al., 2010). Neverthe-
less, ﬂuoxetine was able to prevent the increased immobility time elic-
ited by ARS, a result similar to previous studies that showed the ability
of ﬂuoxetine to abolish the increased immobility time in the mouse
FST elicited by restraint stress (Capra et al., 2010; Moretti et al., 2013).
It should be noted that, as none of the groups presented signiﬁcant dif-
ferences in the open ﬁeld test, possible interferences of the ARS proce-
dure or treatments in the locomotor activity can be ruled out.
The analysis of lipid peroxidation conﬁrmed theoccurrence of oxida-
tive damage since an increased amount ofMDAwas found in the hippo-
campus of mice submitted to ARS. This alteration that follows the
submission of rodents to this procedure was also observed in several
other studies, reinforcing that this animal model is capable of generat-
ing an oxidative stress response (Ahmad et al., 2012; Fontella et al.,
2005; Freitas et al., 2014). In addition, oral administration of guanosine
before ARS prevented the enhanced hippocampal lipid peroxidation ob-
served in TBARS assay, suggesting the occurrence of a neuroprotective
effect in mice treated with this nucleoside. Taking into account that ox-
idative alterations are increasingly being recognized as a critical route of
damage in the pathophysiology of stress-induced depression (Maes
et al., 2011a), the ability of guanosine to prevent stress-related behav-
ioral changes in FST is likely related to this protective effect against hip-
pocampal oxidative damage. It is noteworthy that this association
between major depression and lipid peroxidation can also be found in
studies with human subjects (Maes et al., 2011a; Tsuboi et al., 2006),
as well as the reduction in MDA levels when patients are treated with
antidepressant drugs (Galecki et al., 2009; Michalakeas et al., 2011).
Indeed, several antioxidant compounds have been reported to pres-
ent antidepressant properties (Aboul-Fotouh, 2013; Lobato et al., 2010;
Srinivasan et al., 2012), including GSH (Rosa et al., 2013). Although al-
terations in GSH levels in depressive subjects were found (Kodydkova
et al., 2009; Rybka et al., 2013), in our study none of the groups present-
ed any signiﬁcant alteration in the hippocampal levels of this antioxi-
dant. However, GSH alterations in human depressive subjects are
assessedmostly in serum and, although a post-mortem study indicated
a decrease in prefrontal cortex (Gawryluk et al., 2011), it still not clear if
hippocampal levels are also altered in human patients. Furthermore, in
line with our ﬁndings, other studies also found that ARS procedure
causes an imbalance in various oxidative/antioxidant parameters with-
out causing changes in GSH levels (Budni et al., 2013; Mendez-Cuesta
et al., 2011; Moretti et al., 2013), which might be related to the cell's
ability to restore GSH levels after pro-oxidative challenges. The GSH-
related antioxidant system was also investigated through the measure-
ment of GPx and GR activities. Regarding these parameters, increased
GPx andGR activitieswere found in the hippocampus ofmice submitted
to ARS procedure, a response that is likely due to an increase in ROS gen-
eration following the stressor. Furthermore, the administration of gua-
nosine prevented this alteration, suggesting that this nucleoside may
attenuate the oxidative damage induced by ARS.
One of the main factors implicated in stress-induced oxidative dam-
age is the overproduction of O2•−, which can lead to neuronal atrophy in
the brain (Seo et al., 2012). Therefore, our study evaluated SOD activityand found that hippocampal activity of this enzyme was increased in
mice submitted to ARS. It is noteworthy that ROS generation triggers a
response that activates the nuclear factor (erythroid-derived-2)-like 2
(Nrf-2), a primary transcriptional regulator of a majority of antioxi-
dants, including SOD and heme oxygenase-1 (HO-1) (Deramaudt
et al., 2013). Thismay be a possible explanation to the increased SOD ac-
tivity that we observed after stress exposure. Besides, although the non-
stressed group treated with guanosine did not show any alteration in
SOD activity, this nucleoside caused a higher increase in the activity of
this enzyme as compared with stressed mice treated with vehicle. In
fact, it is reported that the neuroprotective effect of guanosine is medi-
ated byHO-1 (Dal-Cim et al., 2012). Considering that an overexpression
of SOD in several tissues is associated with increased HO-1 levels (Fan
et al., 2012; Khalaj et al., 2013; Turkseven et al., 2005), further studies
are necessary to establish the direct relationship between the
antidepressant-like effect of guanosine and the antioxidant response.
The increased SOD activity in stressedmicemay generate signiﬁcant
amounts of H2O2, which, in turn, could stimulate enzymes that convert
this peroxide into water and molecular oxygen. Indeed, this can be one
explanation for the increased GPx activity found in stressed mice treat-
ed with vehicle although our data also demonstrated that the ARS pro-
cedure leads to a reduction in CAT activity in this group. However, this
result is in line with other studies that found a reduction in CAT activity
in the hippocampus following ARS procedure (Freitas et al., 2014;
Khalaj et al., 2013; Kumar et al., 2010). H2O2 can be metabolized into
OH• and its excessive generation may be involved in the initiation of
the lipid peroxidation observed in the present study, since an enhanced
SOD activity was associated with a decline in CAT. Furthermore, the
analysis of SOD/CAT ratio did not show a signiﬁcant imbalance in ARS-
subjected mice treated with guanosine. This observation may be due
to the fact that, although this nucleoside triggers a response that raised
SOD activity in ARS-subjectedmice, excessive H2O2 may be at least par-
tially neutralized by CAT,whose activitywas not changed (in opposition
to animals subjected to ARS alone).
Despite the fact that major depression is one of the most common
psychiatry disorders and is associated with high rates of disability, the
therapeutic alternatives present a variety of side effects and a lag period
of several weeks in the onset of action (Covington et al., 2010; Zarate
et al., 2006). In this context, it has been demonstrated that antioxidant
compounds as well as glutamate modulators are promising targets for
new therapeutic alternatives in the treatment of this disorder (Niciu
et al., 2014; Scapagnini et al., 2012). Since excitotoxicity and oxidative
stress are reported to act synergistically to induce neuronal damage
(Trotti et al., 1998), guanosine may be proposed as a putative antide-
pressant agent. Interestingly enough, this compoundmay be promising
for themanagement of depression considering its low toxicity (Schmidt
et al., 2010).5. Conclusions
Altogether, our data demonstrated that the oral administration of
guanosine prevented behavioral alterations in the FST as well as hippo-
campal oxidative imbalance in animals subjected to the ARS protocol.
The present study reinforces the notion that this nucleoside may be an
endogenousmoodmodulator endowedwith neuroprotective properties.Acknowledgments
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